Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis Publisher



Naser Moghadasi A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Expert Opinion on Biological Therapy Published:2025


Abstract

[No abstract available]
Related Docs
1. Clinical and Radiological Activity After Extended Interval and Standard Interval Dosing of Ocrelizumab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2025)
2. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
3. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
4. Recent Advances in Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Clinical Applications and Challenges, Frontiers in Cell and Developmental Biology (2025)
5. Comparing Infusion-Related Reactions of the First Full Dose (600 Mg) Biosimilar Ocrelizumab Administration With the Standard Divided Protocol in Multiple Sclerosis Patients: A Randomized Controlled Trial Study, Acta Neurologica Belgica (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (2)
Nima Rezaei (1)